A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus
Phase 3
Completed
632
2026-04
Industry sponsor intelligence
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Clinical Pipeline.
Lead-sponsor view of CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 632
Pipeline overview
Programs by phase and activity.
Velocity
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Dulaglutide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. studies.
This page groups studies where CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates